Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
11:25am, Monday, 22'nd Dec 2025
AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.
Signal Advisors Wealth LLC Takes $473,000 Position in AstraZeneca PLC $AZN
05:33am, Monday, 22'nd Dec 2025
Signal Advisors Wealth LLC bought a new position in shares of AstraZeneca PLC (NASDAQ: AZN) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm boug
AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial
02:39am, Monday, 22'nd Dec 2025
The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial
02:22am, Monday, 22'nd Dec 2025
AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell l
AstraZeneca (LON:AZN) Reaches New 12-Month High – Should You Buy?
03:32am, Sunday, 21'st Dec 2025
Shares of AstraZeneca PLC (LON: AZN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as £154.74 and last traded at £135.85, with a volume of 42252
AstraZeneca PLC $AZN Position Boosted by Benson Investment Management Company Inc.
03:22am, Sunday, 21'st Dec 2025
Benson Investment Management Company Inc. raised its holdings in shares of AstraZeneca PLC (NASDAQ: AZN) by 18.6% during the undefined quarter, according to its most recent 13F filing with the Securit
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
06:25pm, Friday, 19'th Dec 2025
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Trump to announce new drug-pricing deals later today
10:45am, Friday, 19'th Dec 2025
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
AstraZeneca: Mispriced Growth Following The Oncology Segment Success
02:30am, Friday, 19'th Dec 2025
AstraZeneca targets $80bn revenue by FY2030, driven by oncology leadership and robust pipeline execution. AZN demonstrates double-digit revenue and EBITDA growth, trading at a discount to high-growth
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now
08:30pm, Thursday, 18'th Dec 2025
These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters.
AstraZeneca PLC $AZN Shares Sold by Chesley Taft & Associates LLC
04:42am, Thursday, 18'th Dec 2025
Chesley Taft and Associates LLC decreased its holdings in shares of AstraZeneca PLC (NASDAQ: AZN) by 4.3% during the undefined quarter, according to its most recent 13F filing with the Securities and
AstraZeneca Gets FDA Nod For Breast Cancer Drug, EU Clearance For Lupus Pen
12:37pm, Tuesday, 16'th Dec 2025
FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo self-injection for lupus.
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
11:46am, Tuesday, 16'th Dec 2025
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
10:46am, Tuesday, 16'th Dec 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
First Look: Ford EV pivot, AI infra slump, Uber suit
07:38am, Tuesday, 16'th Dec 2025
Stock News Ford pivots from pure EVs, takes $19.5B charge: Ford Motor (F) will record about $19.5 billion in special items tied to a pullback from all-electric
